6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Retinal asymmetry in multiple sclerosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In a large community-based study, Petzold et al. show that optical coherence tomography measures of retinal asymmetry have high diagnostic sensitivity for multiple sclerosis, particularly in younger individuals without relevant comorbidities. The technique should be considered in future revisions of diagnostic criteria.

          Abstract

          The diagnosis of multiple sclerosis is based on a combination of clinical and paraclinical tests. The potential contribution of retinal optical coherence tomography (OCT) has been recognized. We tested the feasibility of OCT measures of retinal asymmetry as a diagnostic test for multiple sclerosis at the community level. In this community-based study of 72 120 subjects, we examined the diagnostic potential of the inter-eye difference of inner retinal OCT data for multiple sclerosis using the UK Biobank data collected at 22 sites between 2007 and 2010. OCT reporting and quality control guidelines were followed. The inter-eye percentage difference (IEPD) and inter-eye absolute difference (IEAD) were calculated for the macular retinal nerve fibre layer (RNFL), ganglion cell inner plexiform layer (GCIPL) complex and ganglion cell complex. Area under the receiver operating characteristic curve (AUROC) comparisons were followed by univariate and multivariable comparisons accounting for a large range of diseases and co-morbidities. Cut-off levels were optimized by ROC and the Youden index. The prevalence of multiple sclerosis was 0.0023 [95% confidence interval (CI) 0.00229–0.00231]. Overall the discriminatory power of diagnosing multiple sclerosis with the IEPD AUROC curve (0.71, 95% CI 0.67–0.76) and IEAD (0.71, 95% CI 0.67–0.75) for the macular GCIPL complex were significantly higher if compared to the macular ganglion cell complex IEPD AUROC curve (0.64, 95% CI 0.59–0.69, P = 0.0017); IEAD AUROC curve (0.63, 95% CI 0.58–0.68, P < 0.0001) and macular RNFL IEPD AUROC curve (0.59, 95% CI 0.54–0.63, P < 0.0001); IEAD AUROC curve (0.55, 95% CI 0.50–0.59, P < 0.0001). Screening sensitivity levels for the macular GCIPL complex IEPD (4% cut-off) were 51.7% and for the IEAD (4 μm cut-off) 43.5%. Specificity levels were 82.8% and 86.8%, respectively. The number of co-morbidities was important. There was a stepwise decrease of the AUROC curve from 0.72 in control subjects to 0.66 in more than nine co-morbidities or presence of neuromyelitis optica spectrum disease. In the multivariable analyses greater age, diabetes mellitus, other eye disease and a non-white ethnic background were relevant confounders. For most interactions, the effect sizes were large (partial ω 2 > 0.14) with narrow confidence intervals. In conclusion, the OCT macular GCIPL complex IEPD and IEAD may be considered as supportive measurements for multiple sclerosis diagnostic criteria in a young patient without relevant co-morbidity. The metric does not allow separation of multiple sclerosis from neuromyelitis optica. Retinal OCT imaging is accurate, rapid, non-invasive, widely available and may therefore help to reduce need for invasive and more costly procedures. To be viable, higher sensitivity and specificity levels are needed.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: found

          Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

          The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research and clinical practice. Scientific advances in the past 7 years suggest that they might no longer provide the most up-to-date guidance for clinicians and researchers. The International Panel on Diagnosis of Multiple Sclerosis reviewed the 2010 McDonald criteria and recommended revisions. The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation. The following changes were made: in patients with a typical clinically isolated syndrome and clinical or MRI demonstration of dissemination in space, the presence of CSF-specific oligoclonal bands allows a diagnosis of multiple sclerosis; symptomatic lesions can be used to demonstrate dissemination in space or time in patients with supratentorial, infratentorial, or spinal cord syndrome; and cortical lesions can be used to demonstrate dissemination in space. Research to further refine the criteria should focus on optic nerve involvement, validation in diverse populations, and incorporation of advanced imaging, neurophysiological, and body fluid markers.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Multiple Sclerosis

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Clinically applicable deep learning for diagnosis and referral in retinal disease

                Bookmark

                Author and article information

                Journal
                Brain
                Brain
                brainj
                Brain
                Oxford University Press
                0006-8950
                1460-2156
                January 2021
                30 November 2020
                30 November 2020
                : 144
                : 1
                : 224-235
                Affiliations
                [1 ] Moorfields Eye Hospital and The National Hospital for Neurology and Neurosurgery , London, UK
                [2 ] UCL Queen Square Institute of Neurology , London, UK
                [3 ] Dutch Expertise Centre for Neuro-ophthalmology and MS Centre, Departments of Neurology and Ophthalmology , Amsterdam UMC, Amsterdam, The Netherlands
                [4 ] NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology , London, UK
                [5 ] Topcon Healthcare Solutions Research and Development , Oakland, New Jersey, USA
                [6 ] Centre for Clinical Brain Sciences, School of Clinical Sciences, NHS Lothian , Edinburgh, UK
                Author notes

                Appendix 1.

                Paul J Foster and Praveen J Patel authors contributed equally to this work.

                Correspondence to: Axel Petzold UCL Institute of Neurology, Queen Square, London, WC1N 3BG E-mail: a.petzold@ 123456ucl.ac.uk
                Author information
                http://orcid.org/0000-0002-0344-9749
                http://orcid.org/0000-0001-6802-8585
                http://orcid.org/0000-0002-9239-745X
                Article
                awaa361
                10.1093/brain/awaa361
                7880665
                33253371
                2e4ca277-0ed7-4477-bd81-cd000ebc03eb
                © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 27 January 2020
                : 15 July 2020
                : 11 August 2020
                Page count
                Pages: 12
                Funding
                Funded by: Eranda Foundation via the International Glaucoma Association;
                Funded by: UK Department of Health;
                Funded by: National Institute for Health Research, DOI 10.13039/501100000272;
                Funded by: Moorfields Eye Hospital NHS Foundation Trust, DOI 10.13039/501100012617;
                Funded by: UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology;
                Funded by: Helen Hamlyn Trust;
                Funded by: Richard Desmond Charitable Trust;
                Funded by: Clinician Scientist award;
                Award ID: CS-2014-14-023
                Funded by: National Institute for Health Research, DOI 10.13039/501100000272;
                Funded by: NHS;
                Funded by: National Institute for Health Research or the Department of Health;
                Funded by: Moorfields Eye Charity, DOI 10.13039/501100017645;
                Funded by: The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust;
                Funded by: Alcon Research Institute, DOI 10.13039/100007817;
                Funded by: The NIHR BRC at Moorfields Eye Hospital;
                Funded by: Eranda Foundation;
                Funded by: International Glaucoma Association, DOI 10.13039/100011377;
                Funded by: Richard Desmond Charitable Trust;
                Categories
                Original Articles
                AcademicSubjects/MED00310
                AcademicSubjects/SCI01870

                Neurosciences
                multiple sclerosis,demyelination,optic neuritis,imaging,biomarkers
                Neurosciences
                multiple sclerosis, demyelination, optic neuritis, imaging, biomarkers

                Comments

                Comment on this article